Novo Nordisk's Oral Ambition Faces a Reimbursement Reckoning
Published on 08/26/2026 at 04:02 | Redaktion boerse-global.de
The math coming out of Berlin is enough to give any health minister pause. Germany's AOK health insurance association has calculated that covering weight-loss injections for all obese patients on statutory insurance could cost up to €45 billion annually. That figure is framed as a warning rather than a policy proposal, yet it crystallizes the central tension now defining Novo Nordisk's investment case: the demand is visible, but whether it converts into paid-for prescriptions is another matter entirely.
The Danish drugmaker's shares have been caught in that gravitational pull between promise and payment. On Tuesday, the stock rose 3.0 percent to €41.44, building on a weekly gain of 4.9 percent and nudging back toward its 50-day moving average of €41.71. The recovery, however, remains a long way from the 52-week high of €54.86 touched in January — a 24 percent gap that underscores how much ground the company has ceded to Eli Lilly's Zepbound in investor sentiment.
A Pipeline Built on Breadth, Not Brawn
Novo's response to the competitive pressure has been characteristically methodical. CEO Mike Doustdar has pushed back against the notion that the obesity market is a winner-take-all contest, arguing instead that differentiated therapies and the oral Wegovy pipeline will allow the company to reclaim lost territory. That rhetoric now has a concrete anchor: the late-stage OASIS-5 study, launched August 12, is testing lower maintenance doses of the Wegovy tablet and is scheduled to run through 2028.
The oral formulation represents Novo's most significant strategic lever in the fight with Lilly, and the company is broadening its research net beyond GLP-1 monotherapy. A microbiome study conducted jointly with Novonesis is exploring whether nutritional supplements derived from the microbiome could amplify the effects of existing GLP-1 drugs, though results are not expected until the second half of 2027. A separate Phase 3 trial, AMAZE 9, is examining the oral candidate Zenagamtide in obesity — though as of August 21, the study had yet to recruit its first participant, a reminder that pipeline breadth and pipeline execution are not the same thing.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
The Reimbursement Question
The AOK's €45 billion calculation is best understood as an upper bound of what full coverage might cost, not a commitment to expand access. European health systems confronting such figures could just as easily tighten prescribing criteria as loosen them, and the political debate over who pays for obesity treatment is likely to remain contentious for years. For Novo, the stakes are existential: if reimbursement remains restricted to narrow patient populations, the addressable market for Wegovy and Ozempic stays capped regardless of how compelling the clinical data look.
There are countervailing forces. Novo's €15 billion buyback program — with 28.9 million B-shares already repurchased — continues to provide structural support to the share price. A Dutch court recently issued an injunction against a compounded semaglutide nasal spray, signaling that the company is enforcing its patent estate aggressively against imitators. That legal vigilance matters for pricing power, which had been a growing concern among investors.
Analyst Divergence and the Pill's Stumble
The analyst community remains split on Novo's trajectory, and the dispersion in price targets tells its own story. Berenberg downgraded the stock from Buy to Hold in mid-August, cutting its target to DKK 305. Days earlier, SB1 Markets had raised its target to DKK 370 while reaffirming a Buy rating. Between those poles sit Goldman Sachs at DKK 285 and Bernstein at DKK 203, the latter maintaining a skeptical stance despite an upward revision.
Part of that skepticism traces to the oral Wegovy rollout, which has underwhelmed on revenue. Second-quarter sales of the pill came in at DKK 3.22 billion, slightly missing the DKK 3.27 billion consensus, even as more than five million prescriptions were written since the January launch. The gap between prescription volume and revenue conversion suggests that reach alone does not guarantee earnings upside — a lesson that applies equally to the reimbursement debate unfolding in Germany.
Production Shadows and the Path Forward
Not everything in Novo's orbit is proceeding smoothly. Scholar Rock was forced to withdraw its European application for a spinal muscular atrophy treatment and plans to resubmit from a different manufacturing site, following problems at a Novo Nordisk facility in Bloomington, Indiana. The issue does not touch the core Ozempic and Wegovy business, but it raises questions about quality control across the company's supply chain — a concern for investors betting on flawless scaling.
The near-term catalysts are now clear. Watch for recruitment progress at AMAZE 9 and for any regulatory movement in Germany or comparable markets responding to the AOK's warning. Should the cost debate shift from modeling exercises to concrete reimbursement steps, even phased ones, the structural demand for semaglutide products would gain a powerful endorsement — one that would resonate beyond Germany as a signal to other European health systems. Until then, the stock's recent bounce looks more like sentiment repair than a fundamental reassessment, and the question of whether the oral tablet delivers on its promise remains the single most important variable in Novo's turnaround story.
Ad
Novo Nordisk Stock: New Analysis - 26 August
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
